STAGE III COLON CANCER AJCC V8
Clinical trials for STAGE III COLON CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III COLON CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III COLON CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail aims to stop BRAF colon cancer in its tracks
Disease control OngoingThis study tests whether adding two targeted drugs (encorafenib and cetuximab) after standard surgery and chemotherapy can lower the chance of cancer coming back in people with a specific genetic type of stage II/III colon cancer (BRAF V600E). Participants either receive the drug…
Matched conditions: STAGE III COLON CANCER AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 26, 2026 11:45 UTC
-
New hope for hard-to-treat colorectal cancer: drug duo aims to shrink tumors
Disease control OngoingThis study tests a combination of two drugs, SX-682 and nivolumab, in people with a specific type of advanced colorectal cancer (RAS-mutated, MSS) that has spread or can't be removed. The goal is to see if the combo can shrink tumors or slow the cancer's growth. About 51 adults w…
Matched conditions: STAGE III COLON CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 11:30 UTC
-
New combo attack on Hard-to-Treat cancers shows early promise
Disease control OngoingThis early-phase trial tests a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (which blocks a DNA repair enzyme)—in people with advanced solid tumors that have a HER2 mutation. The goal is to find the safest dose and see if the combo wo…
Matched conditions: STAGE III COLON CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:30 UTC
-
Immunotherapy combo shows promise in High-Risk colon cancer trial
Disease control OngoingThis study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps prevent cancer from returning in people with stage III colon cancer that has a specific DNA repair problem (dMMR). About 712 participants received either chemotherapy alone or chemo…
Matched conditions: STAGE III COLON CANCER AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:29 UTC
-
New drug cocktail aims to shrink Hard-to-Treat colorectal tumors
Disease control OngoingThis study tests whether adding two targeted drugs (LY3214996 and abemaciclib) to the standard drug cetuximab can shrink tumors in people with advanced colorectal cancer that no longer responds to standard treatment. About 46 adults with metastatic or inoperable colorectal cancer…
Matched conditions: STAGE III COLON CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
Could adding an immunotherapy drug shrink tough colorectal tumors?
Disease control OngoingThis study is for people with a specific type of advanced colorectal cancer that has a BRAF gene mutation and is stable (not the MSI-high type). It compares the usual two-drug treatment (encorafenib and cetuximab) against the same two drugs plus an immunotherapy drug called nivol…
Matched conditions: STAGE III COLON CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Cancer costs under the microscope: new study follows Patients' financial struggles
Knowledge-focused OngoingThis study looks at how cancer treatment affects the finances of people with stage I to III colon or rectal cancer. Researchers will ask about 565 patients' costs and quality of life over a year. The goal is to understand the financial burden and help doctors better support patie…
Matched conditions: STAGE III COLON CANCER AJCC V8
Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Knowledge-focused
Last updated May 26, 2026 11:45 UTC